Rapport Therapeutics Director Reports $20.36 Million Share Acquisition
Director James Healy reported a $20.36 million acquisition of common shares.
Related stories
Microsoft Outlook Begins Returning After Global Microsoft 365 Disruption
Microsoft said it was working to restore email access after a global Microsoft 365 disruption. Industry executives warned of risks from dependence on a single technology provider.
M impact | EQUITY | Nov 14, 2026, 04:31 AM UTC
Tesla sells Cybercab to first private customers
Reuters reports Tesla is offering its Cybercab to its first private customers.
M impact | EQUITY | Nov 14, 2026, 04:23 AM UTC
Microsoft says affected services fully recovered
L impact | EQUITY | Nov 14, 2026, 04:14 AM UTC
Eicher Motors Q2 Net Profit Rises 15% but Misses Estimates
Second-quarter consolidated net profit rose 15% year on year to 1,573 crore, below analysts’ estimates. Rising raw-material costs offset gains from strong motorcycle sales.
M impact | EQUITY | Nov 14, 2026, 04:12 AM UTC
Warburg Pincus to Acquire 38% Stake in Pricol Unit for ₹1,663 Crore
Warburg Pincus will acquire the stake through affiliate Topaz Terrace Investments, according to a stock exchange disclosure.
M impact | EQUITY | Nov 14, 2026, 04:12 AM UTC
Southwest Resumes Limited Flights This Evening
Southwest Airlines says it is resuming a limited number of flights this evening after consulting with the FAA.
M impact | EQUITY | Nov 14, 2026, 04:02 AM UTC